EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib

Zhigang Liu iD, James L Alexander iD, Kai Yee Eng, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Laura Constable, Rocio Castro Seoane, Claire Bewshea iD, Rachel Nice, Andrea D'Mello, Gareth R Jones und 21 weitere

Journal of Crohn's and Colitis · 2024

DOI: 10.1093/ecco-jcc/jjad182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Crohn's and Colitis, 2024. Verfasst von Zhigang Liu und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Piperidines, Influenza Vaccines, Pyrimidines, Infliximab. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with inflammatory bowel disease [IBD].

Methods

We conducted a prospective study including 213 IBD patients and 53 healthy controls: 165 who had received seasonal influenza vaccine and 101 who had not. IBD medications included infliximab, thiopurines, infliximab and thiopurine combination therapy, ustekinumab, vedolizumab, or tofacitinib. The primary outcome was antibody responses against influenza/A H3N2 and A/H1N1, compared to controls, adjusting for age, prior vaccination, and interval between vaccination and sampling.

Results

Lower antibody responses against influenza A/H3N2 were observed in patients on infliximab (geometric mean ratio 0.35 [95% confidence interval 0.20–0.60], p = 0.0002), combination of infliximab and thiopurine therapy (0.46 [0.27–0.79], p = 0.0050), and tofacitinib (0.28 [0.14–0.57], p = 0.0005) compared to controls. Lower antibody responses against A/H1N1 were observed in patients on infliximab (0.29 [0.15–0.56], p = 0.0003), combination of infliximab and thiopurine therapy (0.34 [0.17–0.66], p = 0.0016), thiopurine monotherapy (0.46 [0.24–0.87], p = 0.017), and tofacitinib (0.23 [0.10–0.56], p = 0.0013). Ustekinumab and vedolizumab were not associated with reduced antibody responses against A/H3N2 or A/H1N1. Vaccination in the previous year was associated with higher antibody responses to A/H3N2. Vaccine-induced anti-SARS-CoV-2 antibody concentration weakly correlated with antibodies against H3N2 [r = 0.27; p = 0.0004] and H1N1 [r = 0.33; p < 0.0001].

Conclusions

Vaccination in both the 2020–2021 and 2021–2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021–2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to influenza/A, similar to COVID-19 vaccine-induced antibody responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesInfluenza VaccinesPyrimidinesInfliximabInflammatory Bowel DiseasesHumansFemaleMaleAdultProspective StudiesMiddle AgedAntibody FormationImmunosuppressive AgentsInfluenza, HumanInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeAntibodies, ViralCase-Control Studies

Stichwörter der Autor:innen

JAK-inhibitoranti-TNFhumoral immunityimmunisation

Substanzen

tofacitinibPiperidinesInfluenza VaccinesPyrimidinesInfliximabImmunosuppressive AgentsAntibodies, Viral

Autor:innen und Institutionen

  • Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
  • Department of Gastroenterology, St Marks Hospital and Academic Institute, Gastroenterology, London, UK.
  • Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
  • Department of Clinical Chemistry, Exeter Clinical Laboratory International, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
  • Division of Medicine & Integrated Care, Imperial College Healthcare NHS Trust, London, UK.

ORCID-Profile: Zhigang Liu, James L Alexander, Claire Bewshea, Shaji Sebastian, Katrina M Pollock, Tariq Ahmad

Förderung

  • Wellcome Trust
  • Medical Research Council
  • Pfizer

Zitieren

APA

Liu, Z., Alexander, J. L., Yee Eng, K., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., Constable, L., Castro Seoane, R., Bewshea, C., Nice, R., D'Mello, A., Jones, G. R., Balarajah, S., Fiorentino, F., Sebastian, S., Irving, P. M., Hicks, L. C., Williams, H. R. T., Kent, A. J., …, & Powell, N. (2024). Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjad182

Vancouver

Liu Z, Alexander JL, Yee Eng K, Ibraheim H, Anandabaskaran S, Saifuddin A, et al. Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib. Journal of Crohn's and Colitis. 2024. doi:10.1093/ecco-jcc/jjad182

BibTeX
@article{Liu2024,
  author = {Liu, Zhigang and Alexander, James L and Yee Eng, Kai and Ibraheim, Hajir and Anandabaskaran, Sulak and Saifuddin, Aamir and Constable, Laura and Castro Seoane, Rocio and Bewshea, Claire and Nice, Rachel and D'Mello, Andrea and Jones, Gareth R and Balarajah, Sharmili and Fiorentino, Francesca and Sebastian, Shaji and Irving, Peter M and Hicks, Lucy C and Williams, Horace R T and Kent, Alexandra J and Linger, Rachel and Parkes, Miles and Kok, Klaartje and Patel, Kamal V and Teare, Julian P and Altmann, Daniel M and Boyton, Rosemary J and Hart, Ailsa L and Lees, Charlie W and Goodhand, James R and Kennedy, Nicholas A and Pollock, Katrina M and Ahmad, Tariq and Powell, Nick},
  title = {Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib},
  journal = {Journal of Crohn's and Colitis},
  year = {2024},
  doi = {10.1093/ecco-jcc/jjad182}
}
Kostenlos starten →